AU2019264092B2 - Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide - Google Patents

Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide Download PDF

Info

Publication number
AU2019264092B2
AU2019264092B2 AU2019264092A AU2019264092A AU2019264092B2 AU 2019264092 B2 AU2019264092 B2 AU 2019264092B2 AU 2019264092 A AU2019264092 A AU 2019264092A AU 2019264092 A AU2019264092 A AU 2019264092A AU 2019264092 B2 AU2019264092 B2 AU 2019264092B2
Authority
AU
Australia
Prior art keywords
mel
tumor
dkla
melittin
anticancer drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019264092A
Other languages
English (en)
Other versions
AU2019264092A8 (en
AU2019264092A1 (en
Inventor
Hyunsu BAE
Jin-Hyun Jeong
Jeong-Dong Kim
Chan-Ju LEE
Do-Ha Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Twinpigbiolab Inc
Original Assignee
Twinpigbiolab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twinpigbiolab Inc filed Critical Twinpigbiolab Inc
Publication of AU2019264092A1 publication Critical patent/AU2019264092A1/en
Publication of AU2019264092A8 publication Critical patent/AU2019264092A8/en
Application granted granted Critical
Publication of AU2019264092B2 publication Critical patent/AU2019264092B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019264092A 2018-05-04 2019-05-07 Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide Ceased AU2019264092B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0051800 2018-05-04
KR20180051800 2018-05-04
PCT/KR2019/005438 WO2019212324A1 (ko) 2018-05-04 2019-05-07 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화

Publications (3)

Publication Number Publication Date
AU2019264092A1 AU2019264092A1 (en) 2020-12-24
AU2019264092A8 AU2019264092A8 (en) 2021-01-07
AU2019264092B2 true AU2019264092B2 (en) 2024-02-15

Family

ID=68386643

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019264092A Ceased AU2019264092B2 (en) 2018-05-04 2019-05-07 Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide

Country Status (8)

Country Link
US (1) US11484601B2 (https=)
EP (1) EP3789041A4 (https=)
JP (1) JP7234349B2 (https=)
KR (1) KR102250412B1 (https=)
CN (1) CN112533640B (https=)
AU (1) AU2019264092B2 (https=)
CA (1) CA3099434C (https=)
WO (1) WO2019212324A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240009269A1 (en) * 2020-11-20 2024-01-11 The Johns Hopkins University Membrane-active peptides and methods for reversible blood- brain barrier opening
CA3153060A1 (en) * 2021-05-07 2022-11-07 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
US20220354957A1 (en) * 2021-05-07 2022-11-10 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
CN113336828B (zh) * 2021-06-30 2022-03-25 中国海洋大学 抗菌肽yhx-3及其组合物和应用
CN114437193A (zh) * 2022-01-29 2022-05-06 陕西未来多肽生物科技有限公司 一种金-蜂毒肽纳米杂化物及其应用
KR20230144960A (ko) * 2022-04-07 2023-10-17 트윈피그바이오랩(주) 신규 펩타이드 기반 면역항암제
WO2023204329A1 (ko) * 2022-04-22 2023-10-26 트윈피그바이오랩(주) 신규 펩타이드 기반 면역항암제
CN115317622B (zh) * 2022-08-12 2025-08-22 青岛科技大学 一种抗肿瘤多肽偶联药物的制备及其应用
CN116589555B (zh) * 2023-03-31 2024-02-06 广东医科大学 一种细胞穿梭肽及其应用
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
KR20250091126A (ko) * 2023-12-12 2025-06-20 트윈피그바이오랩(주) 신규 펩타이드를 유효성분으로 포함하는 항암제와의 병용투여를 위한 항암 조성물
CN120053399A (zh) * 2025-02-27 2025-05-30 滁州学院 一种蜂毒肽靶向制剂及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699896A (zh) * 2016-12-05 2017-05-24 华中科技大学同济医学院附属协和医院 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
BRPI0923283A2 (pt) 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
KR20110117789A (ko) 2010-04-22 2011-10-28 대한민국(농촌진흥청장) 멜리틴을 함유하는 동맥경화 치료용 조성물
KR20110117788A (ko) 2010-04-22 2011-10-28 대한민국(농촌진흥청장) 멜리틴을 포함하는 섬유아세포-유사-활막세포의 활성을 억제하는 조성물
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
KR101935095B1 (ko) * 2015-07-31 2019-01-04 이화여자대학교 산학협력단 신규한 세포투과성 펩타이드
KR102073273B1 (ko) 2017-08-23 2020-03-02 (주) 레느스랩 멜리틴을 포함하는 m2형 종양관련 대식세포 제거용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699896A (zh) * 2016-12-05 2017-05-24 华中科技大学同济医学院附属协和医院 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE ET AL: "Development of melittin-based anti-cancer drug for targeting tumor-associated macrophages", THE JOURNAL OF IMMUNOLOGY, vol. 200, no. 1, supplement, 1 May 2018 (2018-05-01), pages 56.22, DOI: 10.4049/JIMMUNOL.1701206 *
RADY I. et al., "Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy", Cancer Letters, 20 May 2017, Vol. 402, pages 16-31, *
SHIN M.C. et al., "Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity", Pharm Res., Sep 2016, Vol 33, No. 9, pages 2218-2228 *

Also Published As

Publication number Publication date
US20210244823A1 (en) 2021-08-12
CA3099434A1 (en) 2019-11-04
AU2019264092A8 (en) 2021-01-07
WO2019212324A1 (ko) 2019-11-07
KR102250412B1 (ko) 2021-05-17
US11484601B2 (en) 2022-11-01
EP3789041A4 (en) 2022-07-13
CN112533640B (zh) 2025-02-28
CN112533640A (zh) 2021-03-19
EP3789041A1 (en) 2021-03-10
KR20190127609A (ko) 2019-11-13
CA3099434C (en) 2023-09-05
AU2019264092A1 (en) 2020-12-24
JP2021526548A (ja) 2021-10-07
JP7234349B2 (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
AU2019264092B2 (en) Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide
JP7386161B2 (ja) 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
US12269902B2 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
Kularatne et al. A CXCR4‐Targeted Site‐Specific Antibody–Drug Conjugate
US10781241B2 (en) Cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof
Klingbeil et al. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance
JP6113850B2 (ja) がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法
US20180079792A1 (en) Peptide having eight amino acid sequences derived from cage and retaining anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug-resistant cancer cells
KR20220152383A (ko) 대식세포를 표적으로 하는 펩타이드, 컨쥬게이트, 조성물 및 그의 용도
US20240156971A1 (en) Methods and sortilin binding conjugate compounds for targeting cancer stem cells
US20220354957A1 (en) Peptides targeting macrophages, and conjugates, compositions, and uses thereof
US12215172B2 (en) Bio-responsive adhesive antibody delivery platform for immunotherapy and preparation method thereof
KR102831503B1 (ko) 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물
KR20210136252A (ko) 항종양 면역 상승효과를 나타내는 종양세포 특이적 자가조립 나노입자
CN111556758B (zh) 细胞杀伤剂
EP4512410A1 (en) Novel-peptide-based anticancer immunotherapeutic agent
US20180230466A1 (en) Methods for treating tumors
Campeiro Potential applications of the cell-penetrating peptide crotamine

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 51 , PAGE(S) 7370 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TWINPIGBIOLAB. INC., APPLICATION NO. 2019264092, UNDER INID (72) CORRECT THE CO-INVENTOR TO LEE, DO-HA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired